

[Siemens, Novartis to develop assays](#)

written by CAP TODAY

December 17, 2020

December 2020—Siemens Healthineers announced a master collaboration agreement with Novartis Pharma to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis' therapeutic pipeline. The initial program will focus on developing a serum neurofilament light chain immunoassay for patients with multiple sclerosis and other neurological diseases.

The tests will run on Siemens Advia Centaur and Atellica immunoassay platforms.

[Siemens Healthineers](#), 888-826-9702



©2026 CAP TODAY, all rights reserved.